Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.

Lachaine, J; Laurier, C; Langleben, A; Vaillant, L

Lachaine, J; Laurier, C; Langleben, A; Vaillant, L.

Affiliation

Lachaine J; Faculty of Pharmacy, University of Montreal, Que, Canada.

Crit Rev Oncol Hematol ; 32(2): 105-12, 1999 Nov.

Article in En | MEDLINE | ID: mdl-10612010

Subject(s)

Antiemetics/economics; Antineoplastic Agents/adverse effects; Breast Neoplasms/drug therapy; Metoclopramide/economics; Ondansetron/economics; Antiemetics/therapeutic use; Canada; Cost-Benefit Analysis; Humans; Metoclopramide/therapeutic use; Middle Aged; Nausea/chemically induced; Nausea/prevention & control; Ondansetron/therapeutic use; Quality of Life; Vomiting/chemically induced; Vomiting/prevention & control

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Breast Neoplasms / Ondansetron / Metoclopramide / Antiemetics / Antineoplastic Agents Type of study: Health_economic_evaluation Limits: Humans / Middle aged Country/Region as subject: America do norte Language: En Year: 1999 Type: Article

Search on Google

XML

PubMed Links